China Resources Pharma's Investment Arm to Divest 5.88% Stake in Tianmai Biotech

Stock News

Mar 16

China Resources Pharma (03320) announced that its wholly-owned subsidiary, China Resources Pharmaceutical Investment Co., Ltd., has initiated the potential sale of approximately 5.88% of its equity interest in Hefei Tianmai Biotech Development Co., Ltd. (Tianmai Biotech). The divestment will be conducted through a public listing on the Shanghai United Assets and Equity Exchange, with a preliminary reserve price set at around RMB 510 million. This potential transaction is separate and independent from the sale of certain equity interests in Tianmai Biotech by China Resources Pharmaceutical Investment and its subsidiaries. As of the date of this announcement, China Resources Pharmaceutical Investment and its subsidiaries collectively hold approximately 23.75% of the equity in Tianmai Biotech.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/news/1106129332"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1106129332\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1106129332?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-16 21:48","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1106129332","market":"us","top_or_hot":-1,"title":"China Resources Pharma's Investment Arm to Divest 5.88% Stake in Tianmai Biotech","media":"Stock News","content":"<p>China Resources Pharma (03320) announced that its wholly-owned subsidiary, China Resources Pharmaceutical Investment Co., Ltd., has initiated the potential sale of approximately 5.88% of its equity interest in Hefei Tianmai Biotech Development Co., Ltd. (Tianmai Biotech). The divestment will be conducted through a public listing on the Shanghai United Assets and Equity Exchange, with a preliminary reserve price set at around RMB 510 million. This potential transaction is separate and independent from the sale of certain equity interests in Tianmai Biotech by China Resources Pharmaceutical Investment and its subsidiaries. As of the date of this announcement, China Resources Pharmaceutical Investment and its subsidiaries collectively hold approximately 23.75% of the equity in Tianmai Biotech.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>China Resources Pharma's Investment Arm to Divest 5.88% Stake in Tianmai Biotech</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nChina Resources Pharma's Investment Arm to Divest 5.88% Stake in Tianmai Biotech\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-03-16 21:48</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>China Resources Pharma (03320) announced that its wholly-owned subsidiary, China Resources Pharmaceutical Investment Co., Ltd., has initiated the potential sale of approximately 5.88% of its equity interest in Hefei Tianmai Biotech Development Co., Ltd. (Tianmai Biotech). The divestment will be conducted through a public listing on the Shanghai United Assets and Equity Exchange, with a preliminary reserve price set at around RMB 510 million. This potential transaction is separate and independent from the sale of certain equity interests in Tianmai Biotech by China Resources Pharmaceutical Investment and its subsidiaries. As of the date of this announcement, China Resources Pharmaceutical Investment and its subsidiaries collectively hold approximately 23.75% of the equity in Tianmai Biotech.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"XBI","symbol_name":"SPDR S&P Biotech ETF","start_time":0,"source_url":"","article_id":"1106129332","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1106129332","pubTimestamp":1773668897,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"China Resources Pharma (03320) announced that its wholly-owned subsidiary, China Resources Pharmaceutical Investment Co., Ltd., has initiated the potential sale of approximately 5.88% of its equity...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"159837":"生物科技","XBI":"SPDR S&P Biotech ETF","03320":"华润医药","BK4588":"碎股","BK1191":"制药","BK1570":"华润系","BK4585":"ETF&股票定投概念","BK4581":"高盛持仓"},"translate_title":"华润医药投资部门将剥离天迈生物5.88%股权","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"159837":1,"03320":1,"XBI":1,"HBImain":1},"content_text":"China Resources Pharma (03320) announced that its wholly-owned subsidiary, China Resources Pharmaceutical Investment Co., Ltd., has initiated the potential sale of approximately 5.88% of its equity interest in Hefei Tianmai Biotech Development Co., Ltd. (Tianmai Biotech). The divestment will be conducted through a public listing on the Shanghai United Assets and Equity Exchange, with a preliminary reserve price set at around RMB 510 million. This potential transaction is separate and independent from the sale of certain equity interests in Tianmai Biotech by China Resources Pharmaceutical Investment and its subsidiaries. As of the date of this announcement, China Resources Pharmaceutical Investment and its subsidiaries collectively hold approximately 23.75% of the equity in Tianmai Biotech.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-1","news_tag":"shareholding","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}